

8. (Amended) A transgenic see-through medaka produced by means of further selective mating between the see-through medaka according to claim 2 and iridophore deficient mutant medaka strain il-1, wherein a specific organ is allowed to produce luminescence by introducing a hybrid gene being a fusion of a promoter of a gene which expresses specifically in said organ, with a coding region of a gene encoding a fluorescent protein.

9. (Amended) A transgenic see-through medaka deficient in iridophores, melanophores and xanthophores, wherein the sex of said medaka can be identified by the presence or absence of leucophores and/or a DNA marker, wherein a specific organ is allowed to produce luminescence by introducing a hybrid gene being a fusion of a promoter of a gene which expresses specifically in said organ, with a coding region of a gene encoding a fluorescent protein.

10. (Amended) A transgenic see-through medaka produced by means of further selective mating between the see-through medaka according to claim 3 and a see-through medaka produced by means of repeated selective mating between iridophore deficient mutant medaka strain gu, albino mutant medaka strain i-3, leucophore deficient mutant medaka strain 1f, and medaka FLF strain which is deficient in leucophores in the female, wherein a specific organ is allowed to produce luminescence by introducing a hybrid gene being a fusion of a promoter of a gene which expresses specifically in said organ, with a coding region of a gene encoding a fluorescent protein.

11. (Amended) The transgenic see-through medaka according to claim 7 wherein said gene encoding the fluorescent protein is a gene encoding a green fluorescent protein.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

12. (Amended) The transgenic see-through medaka according to claim 8 wherein said gene encoding the fluorescent protein is a gene encoding a green fluorescent protein.

13. (Amended) The transgenic see-through medaka according to claim 9 wherein said gene encoding the fluorescent protein is a gene encoding a green fluorescent protein.

14. (Amended) The transgenic see-through medaka according to claim 10 wherein said gene encoding the fluorescent protein is a gene encoding a green fluorescent protein.

15. (Amended) The transgenic see-through medaka according to claim 7 wherein said organ is a gonadal organ.

16. (Amended) The transgenic see-through medaka according to claim 8 wherein said organ is a gonadal organ.

17. (Amended) The transgenic see-through medaka according to claim 9 wherein said organ is a gonadal organ.

18. (Amended) The transgenic see-through medaka according to claim 10 wherein said organ is a gonadal organ.

19. (Amended) The transgenic see-through medaka according to claim 11 wherein said organ is a gonadal organ.

20. (Amended) The transgenic see-through medaka according to claim 12 wherein said organ is a gonadal organ.

21. (Amended) The transgenic see-through medaka according to claim 13 wherein said organ is a gonadal organ.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B1
COPY

22. (Amended) The transgenic see-through medaka according to claim 14 wherein said organ is a gonadal organ.

Please add the following new claims 23-30:

July
E1

23. (New) A transgenic see-through medaka produced by means of repeated selective mating between iridophore deficient mutant medaka strain gu, albino mutant medaka strain i-3 and leucophore deficient mutant medaka strain 1f, wherein a specific organ is allowed to produce luminescence by introducing a hybrid gene being a fusion of a promoter of a gene which expresses specifically in said organ, with a coding region of a gene encoding a fluorescent protein.

B2

24. (New) A transgenic see-through medaka produced by means of repeated selective mating between iridophore deficient mutant medaka strain gu, albino mutant medaka strain i-3, leucophore deficient mutant medaka strain 1f and medaka FLF strain which is deficient in leucophores in the female, wherein a specific organ is allowed to produce luminescence by introducing a hybrid gene being a fusion of a promoter of a gene which expresses specifically in said organ, with a coding region of a gene encoding a fluorescent protein.

25. (New) The transgenic see-through medaka according to claim 23 wherein said gene encoding the fluorescent protein is a gene encoding a green fluorescent protein.

26. (New) The transgenic see-through medaka according to claim 24 wherein said gene encoding the fluorescent protein is a gene encoding a green fluorescent protein.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com